Molika Ashford

The firm said the new version of its colon cancer screening test improved upon its predecessor across a variety of metrics, including both sensitivity and specificity.

MRD assays show promise in immunotherapy response prediction with the potential to guide dose/treatment escalation with emerging adjuvant approaches.

New data presented at the ASCO annual meeting this week showed that tumor-informed assays could detect emerging recurrence ahead of imaging.

Real-world and trial data shored up evidence that the company's multi-cancer detection assay can guide follow-up assessment of patients with a positive result.

The company is seeing continuing growth for its existing clinical products as it moves resources toward commercialization of its Guardant Shield CRC screening test.

Exact reported revenues of $602.5 million compared to $486.6 million a year ago, surpassing analysts' average estimate of $543.5 million.

The company managed an eighth consecutive quarter of year-over-year per-test revenue growth as it prepares to enter new markets like minimal residual disease testing.

The company's testing revenues rose 29 percent in Q1 thanks to increased adoption of its Decipher Prostate and Afirma tests.

The company discussed what it believes are compelling new results on the impact of its testing on patient outcomes during a call discussing its Q1 earnings.

The company recently presented its first assay performance data in a multi-cancer setting, showing high accuracy, even in the most challenging tumor types.